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patients with moderate-to-severe AD and clinically relevant 
sensitization to birch pollen received SIT for 12 weeks. SIT 
was continued during birch pollen season. The assessment 
of safety, the total SCORAD value, and the Dermatology Life 
Quality Index (DLQI) were evaluated.  Results: The median 
total SCORAD value was reduced by 34% (p  ! 0.001) during 
the course of treatment and the mean DLQI improved by 
49% (p  ! 0.001) despite strong simultaneous birch pollen ex-
posure. Eight patients (14.5%) developed systemic reactions 
and 19 patients (34.5%) developed local reactions which 
were of mild intensity in most cases. No patient discontinued 
the study prematurely due to adverse drug reactions. Cosea-
sonal treatment was well tolerated.  Conclusion: SIT with a 
depigmented polymerized birch pollen extract leads to sig-
nificant improvement of the SCORAD value and the DLQI in 
patients suffering from moderate-to-severe AD sensitized to 
birch pollen. 
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 Abstract 
 Background: Birch pollen is an important outdoor allergen 
able to aggravate symptoms in atopic dermatitis (AD). Spe-
cific immunotherapy (SIT), an established procedure for al-
lergic airway diseases, might also represent an attractive 
therapeutic option for the causal treatment of allergen-trig-
gered cutaneous symptoms in these patients. Studies with 
house dust mite SIT have already shown beneficial effects in 
AD patients, whereas the safety and efficacy of SIT with birch 
pollen extract in AD patients have not been studied so far. 
The aim of this study was to evaluate for the first time the 
safety and efficacy of SIT with a depigmented polymerized 
birch pollen extract in AD patients.  Methods: Fifty-five adult 
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 Introduction 
 To date, therapy for atopic dermatitis (AD), a frequent 
chronic inflammatory skin disease, is limited to symp-
tomatic anti-inflammatory, antipruritic, or immuno-
modulatory treatment approaches  [1] . However, ratio-
nale-based treatment conducted to counteract disease-
aggravating pathways induced by trigger factors for AD 
would be much more effective in reducing the number of 
flare-ups and the severity of AD, thereby improving the 
quality of life of these patients. Although it is still unclear 
whether allergic sensitizations mirrored by elevated total 
serum immunoglobulin E (IgE) and allergen-specific IgE 
levels detectable in a majority of AD patients represent 
primary or secondary disease-related factors, indoor al-
lergens such as house dust mites (HDM) as well as sea-
sonal allergens including birch and grass pollen allergens 
have been clearly shown to promote exacerbations and 
impairment of the disease  [2] .
 Allergens represent important triggers in a majority of 
AD patients. Allergen-specific immunotherapy is suc-
cessfully in use as a long-term treatment of sensitizations 
in patients with related atopic disorders such as rhinitis 
and mild asthma. The efficacy of specific immunothera-
py (SIT) in rhinitis and mild asthma is well proven and is 
related to immunologic changes such as a shift of Th2 
immune responses into modified Th1 immune responses 
as well as the induction of regulatory T cells and other 
tolerogenic pathways  [3, 4] . Thus, the first open-label and 
controlled studies on SIT have been conducted in AD pa-
tients with sensitizations to HDM. Altogether, most of 
these studies have provided very promising results  [5, 6] . 
However, most of the controlled and uncontrolled studies 
published on this topic so far have focused on the treat-
ment of sensitizations to HDM or grass pollen allergens 
in AD patients  [7] , but none of the studies have investi-
gated the safety and efficacy of SIT in AD patients sensi-
tized to birch pollen allergen. As a consequence, at pres-
ent there are no data available which would allow any 
reliable assessment of the value of SIT with birch pollen 
allergens as a rationale-based treatment approach for AD.
 Therefore, we performed a multicenter, open, pilot 
study in adult patients with AD and clinically relevant 
sensitizations to birch pollen allergen.
 Methods 
 Patients and Diagnostic Criteria 
 A total of 55 AD patients between 18 and 65 years of age with 
moderate-to-severe AD diagnosed according to the criteria of 
Hanifin and Rajka were included. Disease severity was assessed 
using a severity scoring of atopic dermatitis (SCORAD)  [8] . Pa-
tients with a SCORAD value  6 25 and a duration of eczema longer 
than 2 years were selected. Birch pollen sensitization was assessed 
by specific serum IgE against birch pollen in CAP-RAST  6 3, a 
positive atopy patch test, and/or a positive skin prick test for birch 
pollen allergen as well as symptoms of AD related to birch pollen 
exposure. The demographic data of the study cohort are summa-
rized in  table 1 . Of the AD patients, 10.9% had concomitant al-
lergic asthma and 5.5% had allergic rhinoconjunctivitis.
 Obligatory exclusion criteria were: FEV 1  ! 70% of the predict-
ed value measured by the peak flow; SIT against  Betula Verrucosa 
( Bet v 1 ;  birch pollen) during the last 5 years; pretreatment with 
systemic corticosteroids, immunosuppressive agents or UV ther-
apy 1 month before SIT or during SIT; acute tuberculosis; inflam-
matory or infectious diseases of the target organ; immunopatho-
logical diseases in which autoimmune mechanisms play a role; 
immune deficiencies; treatment with   -antagonists; any disease 
prohibiting the use of adrenaline; serious psychiatric and psycho-
logical disturbances; concomitant treatment with substances in-
terfering with the immune system; pregnancy; immunization 
with vaccines 7 days prior to SIT and 14 days post-SIT, and acute 
and chronic eczema at the skin prick test site.
 Study Design 
 The study was designed as an open-label pilot study to assess 
the safety and efficacy of SIT with depigmented birch pollen ex-
tract in AD patients. The study was conducted from January 2008 
to January 2009. The regional pollen count measurement was 
documented at each center. The use of concomitant medications 
with emollients and topical and systemic drugs was regularly doc-
umented in each patient. The study was approved by the ethics 
committee and informed consent was obtained from every indi-
vidual participating in the study.
 Allergen Preparation and Treatment Schedule 
 The treatment was subdivided into a build-up phase of 3 weeks 
followed by a maintenance treatment period of 12 weeks with SIT 
using a depigmented polymerized birch pollen extract. The initial 
build-up period during the first 3 weeks after screening consisted 
of weekly administrations of gradually increasing amounts of vial 
1 at a concentration of 100 DPP/mI and vial 2 at a concentration 
of 1,000 DPP/ml (1 DPP was the result of depigmenting and po-
Table 1.  Summary of the demographic baseline characteristics
Demographic variables Overall (n = 55)
Gender
Male, n (%) 20 (36.4)
Female, n (%) 35 (63.6)
Age, years 36.3810.7
Total serum IgE, kU/l 2,181.684,169.9
Birch pollen-specific IgE, kU/l 77.8832.9
 Values are presented as means8SD unless otherwise specified. 
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lymerizing 1 HEPL of birch pollen allergenic extract). Treatment 
started with 7-day administration intervals of gradually increas-
ing single doses of extract until the recommended dose was 
reached (i.e. 0.2 ml vial 1, 0.5 ml vial 1, 0.2 ml vial 2, and 0.5 ml 
vial 2). This dose (0.5 ml of vial 2) was further maintained over 
the remaining treatment period in 6-week intervals for a total 
maintenance phase of 12 weeks ( table 2 ). Regular patient visits 
were before SIT as well as at weeks 1, 2, 3, 9, and 15. A follow-up 
visit was conducted 2 weeks after the end of SIT. Treatment was 
started before and continued during the birch pollen season.
 Statistical Analysis 
 Statistical analysis was performed with SPSS 17.0 for Windows 
using a t test for normally distributed samples. The calculated 
values shown are means  8 standard error of the mean (SEM).
 Results 
 Significant Improvement of the SCORAD Value and 
the Dermatology Life Quality Index under SIT 
 The median total SCORAD value decreased by 34%
(p  ! 0.001) during the course of treatment ( fig. 1 a). The 
mean Dermatology Life Quality Index (DLQI) improved 
by 49% (p  !  0.001), indicating a profound positive influ-
ence of SIT not only on the clinical symptoms of AD but 
also on patients’ quality of life ( fig. 1 b). Furthermore, it is 
important to note that improvement was already notice-
able after the build-up phase, with continuous improve-
ment of the total SCORAD value and the DLQI until the 
end of treatment.
 The Frequency of Side Reactions Was Comparable to 
Other Studies on SIT with Depigmented Birch Pollen 
Extract 
 A total of 24 patients developed adverse drug reac-
tions. Eight patients (14.5%) developed systemic reactions 
which were mostly of mild intensity and consisted of 
flare-ups of eczematous (2 patients) or urticarial skin le-
sions, a worsening of the symptoms of rhinitis, an in-
crease in pruritus, transient headache, or vertigo. Nine-
Table 2. S ummary of the SIT schedule
Vial Injection No. Interval Milliliters
1 1 1 week 0.2
2 1 week 0.5
2 3 1 week 0.2
4 1 week 0.5
5+6 6 weeks 0.5
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 Fig. 1. The SCORAD value and the DLQI decrease significantly 
under SIT.  a The mean values of the total SCORAD value  8 SEM 
during different weeks of SIT are depicted.  b The mean values of 
the DLQI  8 SEM during treatment are shown.  *  p  !  0.05;  * *  p  ! 
 0.001; no indication = Not significant; w = week. 
Table 3.  Summary of side effects observed during the study
Symptoms Patients, n (%) Symptoms, n
Eczematous flare 2 (3.6) 2
Pruritus 2 (3.6) 2
Procedural headache 1 (1.8) 1
Allergic rhinitis 1 (1.8) 1
Urticaria 1 (1.8) 1
Vertigo 1 (1.8) 1
Local reactions 19 (34.5) 36
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teen patients (34.5%) developed local reactions, 30% of 
which occurred immediately after injection. Local side 
reactions were mostly of mild intensity ( table 3 ). No pa-
tient discontinued the study prematurely due to adverse 
drug reactions. Based on a calculated weekly dose, usage 
of the concomitant medications was constant before, dur-
ing, and after SIT, indicating that there was no negative 
influence of SIT on AD. Moreover, the use of systemic 
antihistamines and nasal sprays decreased during SIT as 
compared to baseline.
 Furthermore, it is important to note that SIT was con-
tinued during birch pollen season; thus, the SCORAD 
value and the DLQI improved despite simultaneous birch 
pollen exposure. On average, every patient was treated for 
19.2 days during birch pollen season. About 60% of pa-
tients reached the maintenance dose until the onset of 
birch pollen season.
 Discussion 
 Here, we demonstrated that the treatment of AD pa-
tients sensitized to birch pollen with SIT leads to pro-
found improvement of the SCORAD value and the DLQI 
already within the first few weeks of therapy.
 Therefore, this study provides the first evidence of the 
safety and efficacy of SIT with a depigmented polymer-
ized birch pollen extract in patients with moderate-to-
severe AD. These data confirm the conceptual approach 
of using SIT for the long-term treatment of sensitizations 
in AD patients, as has been done in rhinitis and mild 
asthma for several years now  [9, 10] . Furthermore, the 
data amend the observations on the safety and efficacy of 
SIT gained in the context of the treatment of AD patients 
with sensitizations against HDM. Despite improvement 
of the skin lesions, a reduction in CCL17, CCL22, and 
other serum factors known to go along with the severity 
of AD has been observed in AD patients during SIT, with 
no significant increase in the total and allergen-specific 
IgE serum levels  [11, 12] .
 Therefore, the results of this study might represent the 
first steps towards an expansion of the therapeutic op-
tions of SIT in AD patients to patients with sensitizations 
to birch pollen allergen.
 When comparing the results of this trial with other 
open-label or controlled studies on SIT in AD, the rela-
tively short treatment phase of only 12 weeks in this study 
has to be considered  [5, 13] . This allows a relatively clear 
assessment of safety but only a preliminary conclusion 
about the efficacy of this treatment, which is already very 
satisfactory after 12 weeks but is likely to be even stronger 
after a longer treatment period.
 Since this study was conducted to assess the first data 
on the safety and efficacy of SIT using a depigmented 
birch pollen extract in adult patients with AD, an open-
label study design was been selected. Therefore, based on 
previous studies with comparable invasive treatments, a 
placebo effect of up to 30% improvement of AD severity 
has to be considered. However, the improvement achieved 
in this study clearly exceeds this effect.
 The frequency of local and systemic side reactions in 
AD patients was comparable to the rate observed in so-far 
unpublished double-blind placebo-controlled studies on 
SIT with depigmented birch/tree pollen extract per-
formed in patients with allergic rhinitis.
 Despite HDM, birch and grass pollen allergens repre-
sent strong exogenous trigger factors in a subgroup of AD 
patients. The relevance of birch pollen allergens for ec-
zema development is further documented by a relatively 
high rate of positive atopy patch test reactions to birch 
pollen allergens as compared to other aeroallergens such 
as grass pollen or cat dander in sensitized AD patients 
 [14] . Moreover, the skin of AD patients with high sensiti-
zation levels to birch pollen allergens is much more colo-
nized with enterotoxin-producing  Staphylococcus aureus 
bacteria, and those patients were demonstrated to suffer 
from more severe forms of AD  [15] . In addition, birch 
pollen-related foods have been observed to provoke flare-
ups of AD as well as the accumulation of birch pollen-
specific T cells in the AD skin lesions of birch pollen-
sensitized patients  [16, 17] . In the long term, treating 
birch pollen-sensitized AD patients with SIT would not 
only allow the efficient therapeutic reduction of birch 
pollen-triggered flare-ups of AD, but it would also puta-
tively impact on the impairment of AD by other cofactors 
associated with birch pollen sensitizations modifying the 
severity of AD, such as bacterial colonization an birch-
related food allergens. However, based on the first data on 
the safety and efficacy of birch pollen SIT in AD present-
ed here, double-blind, placebo-controlled, pivotal studies 
are required to confirm and further verify the value of 
birch pollen SIT as an alternative therapeutic option for 
patients with AD.
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